Efficacy and safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Brimapitide (Primary)
- Indications Sensorineural hearing loss
- Focus Registrational; Therapeutic Use
- Acronyms HEALOS
- Sponsors Auris Medical
- 23 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
- 23 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
- 07 Aug 2017 Auris Medical expects to announce top-line results from this trial in the fourth quarter of this year, according to a company media release.